Menarini Group’s Orserdu gets EC approval for breast cancer treatment
The approval was supported by data from the Phase 3 EMERALD trial in which Orserdu showed statistically significant…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Sep 23
The approval was supported by data from the Phase 3 EMERALD trial in which Orserdu showed statistically significant…
21 Sep 23
On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in…
20 Sep 23
Co-developed by Japan-based Otsuka and British Astex, Inaqovi has been cleared by EC as monotherapy in AML patients…
20 Sep 23
Tevimbra is a humanised IgG4 anti-PD-1 monoclonal antibody designed to lower binding to Fc-gamma (Fcγ) receptors on macrophages,…
20 Sep 23
Rhythm is evaluating setmelanotide in a global Phase 3 clinical trial in acquired hypothalamic obesity and expects to…
20 Sep 23
Acceptance based on results from the Phase 3 LITESPARK-005 trial, which showed a statistically significant and clinically meaningful…
19 Sep 23
The approval was based on the findings from the MOMENTUM study and a subpopulation of anaemia patients from…
15 Sep 23
Following the CHMP's positive opinion, the European Commission will decide whether to approve the modified Covid-19 vaccine from…
14 Sep 23
The decision to discontinue the trial was based on the recommendation of the Data Safety Monitoring Board (DSMB)…
14 Sep 23
Investment will support rapid growth of Sempre's life sciences and payer networks and expansion into adjacent product areas